Sexual Dysfunctions, Psychological Clinical Trial
Official title:
Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties
The purpose of this study is to pilot test and determine the feasibility of a
psychoeducational intervention (PED) we recently developed in a group format for women with
acquired sexual arousal disorder (FSAD).
HYPOTHESES:
- 1 - Compared to baseline measures, the PED will result in significant improvement in
self-report measures of: (a) subjective sexual arousal; (b) perception of genital
arousal/genital sensitivity; (c) orgasmic experience; (d) sexual desire; (e) sexual
distress; (f) relationship satisfaction; (g) depressive symptoms; and (h) quality of
life.
- 2 - It is unknown what effect the PED will have on actual physiological sexual arousal.
- 3 - The group format will be a feasible and cost-effective method of delivering
empirically supported treatment to women with sexual arousal difficulties and will
contribute towards meeting the needs for sexual health care for women on the clinic
wait-list at the BC Centre for Sexual Medicine.
Sexual arousal difficulties are common among women, affecting approximately 22% of women
between the ages of 18 and 59 (Laumann, Paik & Rosen, 1999). Although there are
evidence-based psychological treatments available for women with orgasmic and pain
disorders, there are currently no empirically-supported treatments for women with acquired
Sexual Arousal Disorder (FSAD). Moreover, there have been numerous attempts to find evidence
for a pharmacological agent effective at treating women's sexual arousal complaints;
however, to date these studies have been inconclusive. Given the significant role that
sexual health plays in quality of life, the fact that effective psychological treatments for
women's sexual dysfunction are not widely available, and the fact that wait-lists to see
health care professionals with expertise in the area of sexual dysfunction are often
unwieldy, there is a need to establish brief, evidence-based approaches to treat women's
acquired FSAD. Psychological therapy in a group format is a standard practice at the BC
Centre for Sexual Medicine. However, in this study we would like to collect information from
participants that would help us in determining the specific efficacy of the PED as well as
identifying demographic or participant variables that might predict a positive response to
the PED. Because we are using this information to determine the treatment's efficacy and
because we will use this information as the basis for a publication, we deem this to be a
research trial in which ethics review is necessary.
OBJECTIVES: We have recently developed and tested a new psychoeducational treatment (PED)
for the treatment of FSAD due to early-stage gynecologic cancer treatment. Our data show
this PED to significantly improve self-reported sexual desire, arousal, mood, relationship
distress, and quality of life. We are currently testing the efficacy of this PED in a larger
sample of cancer survivors with FSAD. The goal for this study is to test our PED in a group
format for women who are currently seeking treatment at the BC Centre for Sexual Medicine
for FSAD. By testing the efficacy of the PED administered in a group format, we hope to
establish some preliminary data supporting the use of brief psychoeducational interventions
for women. These pilot data will be used in a future larger-scale trial that involves
randomization to group PED or a control condition in order to more definitively establish
the PED efficacy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00996372 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00996164 -
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
Completed |
NCT01188720 -
Sexual Health on Antidepressants Through Physical Exercise
|
N/A | |
Completed |
NCT04792177 -
Internet-based Emotion Regulation Intervention for Sexual Health
|
N/A | |
Completed |
NCT02381912 -
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
|
N/A | |
Completed |
NCT03241524 -
Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women
|
N/A | |
Completed |
NCT00491829 -
Flibanserin Versus Placebo in Premenopausal Women With HSDD
|
Phase 3 | |
Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
Recruiting |
NCT05489133 -
Early Psychological Intervention After Rape
|
N/A | |
Completed |
NCT03775239 -
Mindfulness as Treatment of Sexological Problems
|
N/A | |
Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
Completed |
NCT01188603 -
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 1 | |
Completed |
NCT01771237 -
HIV Prevention Among Vulnerable Male Youth
|
N/A | |
Completed |
NCT00360555 -
A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00360529 -
24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00360243 -
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
|
Phase 3 | |
Recruiting |
NCT05456919 -
Quality of Sexual Function in BRCA Mutated Women
|
||
Terminated |
NCT01040208 -
12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress
|
Phase 3 | |
Terminated |
NCT01057901 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
|
Phase 3 |